Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Niza, Enrique; Ocaña, Alberto; Castro‐Osma, José A.; Bravo, Iván; Alonso‐Moreno, Carlos

doi:10.3390/cancers13143387

Cited by 30 publications

(28 citation statements)

References 121 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These nanoparticles have several advantages: (i) because of their small size, which normally does not exceed 100 nm, and their lipophilicity, they can cross the blood–brain barrier and accumulate at the tumor site as a result of the enhanced permeability and retention (EPR) effect; (ii) they can be loaded with different drugs. (iii) Finally, liposomes and polymeric nanoparticles ensure elimination of the product and limited toxicity because they are biodegradable [ 112 , 113 ].…”

Section: How To Facilitate Brain Diffusion Of Anti-cancer Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier

Angeli

Bousquet

2021

Pharmaceutics

View full text Add to dashboard Cite

The incidence of brain metastases has been increasing constantly for the last 20 years, because of better control of metastases outside the brain, and the failure of most drugs to cross the blood–brain barrier at relevant pharmacological concentrations. Recent advances in the molecular biology of cancer have led to the identification of numerous molecular alterations, some of them targetable with the development of specific targeted therapies, including tyrosine kinase inhibitors. In this narrative review, we set out to describe the state-of-the-art in the use of tyrosine kinase inhibitors for the treatment of melanoma, lung cancer, and breast cancer brain metastases. We also report preclinical and clinical pharmacological data on brain exposure to tyrosine kinase inhibitors after oral administration and describe the most recent advances liable to facilitate their penetration of the blood–brain barrier at relevant concentrations and limit their physiological efflux.

show abstract

Section: How To Facilitate Brain Diffusion Of Anti-cancer Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier

Angeli

Bousquet

2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…(Ge et al, 2014;Chung, Leon, and Rinaldi 2019). In the field of drug delivery, the drug is encapsulated into nanoparticles (NPs) (Niza et al, 2021). The mechanism of action of such NPs is based on the enhanced permeability and retention effect (EPR) to favour its delivery to the site of interest by convection and diffusion processes (Yhee et al, 2013).…”

Section: Advantages and Disadvantages Of Protacs Technologymentioning

confidence: 99%

“…Natural biodegradable polymers such as alginate or chitosan have been widely used to formulate polymeric NPs. These raw materials are biocompatible and biodegradable but face serious drawbacks for PROTACs encapsulation and their clinical translation (Gagliardi et al, 2021;Niza et al, 2021). The high immunogenicity of some natural polymers is a considerable limitation but the high variability in batch productions severely dampened the interest of researchers.…”

Section: Polymeric Nps For the Controlled Release Of Protacsmentioning

confidence: 99%

“…The high immunogenicity of some natural polymers is a considerable limitation but the high variability in batch productions severely dampened the interest of researchers. Synthetic polyesters are biocompatible and biodegradable and can be designed to modulate loading, release kinetics, and stability (Niza et al, 2021). The most widely used polyester as raw material for NPs formulation is PLGA, due to its high biocompatibility and biodegradability.…”

Section: Polymeric Nps For the Controlled Release Of Protacsmentioning

confidence: 99%

“…Indeed, it was approved by the FDA for clinical use (Lü et al, 2014). Polymeric NPs can be synthesized towards different techniques like emulsification, nanoprecipitation, ion gelation, and microfluidics, to produce NPs with different properties (Niza et al, 2021). The therapeutic agent can be physically retained or absorbed by the polymer matrix formulating nanospheres or can be dissolved entrapped in a shell disposed around an oily core to form nanocapsules.…”

Section: Polymeric Nps For the Controlled Release Of Protacsmentioning

confidence: 99%

See 2 more Smart Citations

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles

Juan¹,

Noblejas-López

Arenas-Moreira³

et al. 2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Classical targeting in cancer focuses on the development of chemical structures able to bind to protein pockets with enzymatic activity. Some of these molecules are designed to bind the ATP side of the kinase domain avoiding protein activation and the subsequent oncogenic activity. A further improvement of these agents relies on the generation of non-allosteric inhibitors that once bound are able to limit the kinase function by producing a conformational change at the protein and, therefore, augmenting the antitumoural potency. Unfortunately, not all oncogenic proteins have enzymatic activity and cannot be chemically targeted with these types of molecular entities. Very recently, exploiting the protein degradation pathway through the ubiquitination and subsequent proteasomal degradation of key target proteins has gained momentum. With this approach, non-enzymatic proteins such as Transcription Factors can be degraded. In this regard, we provide an overview of current applications of the PROteolysis TArgeting Chimeras (PROTACs) compounds for the treatment of solid tumours and ways to overcome their limitations for clinical development. Among the different constraints for their development, improvements in bioavailability and safety, due to an optimized delivery, seem to be relevant. In this context, it is anticipated that those targeting pan-essential genes will have a narrow therapeutic index. In this article, we review the advantages and disadvantages of the potential use of drug delivery systems to improve the activity and safety of PROTACs.

show abstract

Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities

Selepe,

Dhlamini,

Tshweu

et al. 2024

Nano Select

View full text Add to dashboard Cite

According to the World Health Organization (WHO), there are more than 2.3 million cases of breast cancer (BC) each year, with 80% of deaths occurring in low‐ and middle‐income countries (LMICs). Chemotherapeutic agents are used in the treatment of BC to kill or slow the growth of cancer cells. While they can be effective in many cases, they also have potential side effects. These include long‐term effects such as possible damage to healthy organs, limited efficacy, and resistance development. Trastuzumab (Tmab) offers superior treatment options due to low toxicity and high specificity for a target antigen. However, Tmab treatment, despite being available for the last two decades, has remained challenging and expensive to manage, and inaccessible to people in underserved communities. Therefore, it is necessary to ensure that such effective medication is within reach of those in need, regardless of social or economic class. Recent advances in nanomedicine have led to a growing number of studies that show promise in meeting these challenges through access to adequate anticancer drugs in LMICs. This review analyzes such reports while highlighting the progress of nanomedicine and anticancer drug systems and presents opportunities that have been overlooked over the years for LMICs.

show abstract

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

Cited by 30 publications

References 121 publications

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles

Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities

Contact Info

Product

Resources

About